Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity.
This study evaluated the telomere length changes (DeltaTL) of peripheral blood mononuclear cells before and after repetitive standard-dose nonmyeloablative chemotherapy and the association of DeltaTL with treatment response and myelosuppression severity. TL was measured with Southern blot analysis in 32 solid-cancer patients without bone marrow metastasis. The mean TL before chemotherapy (t0 TL) and after the 2nd (t1 TL), 4th (t2 TL) and 6th cycle (t3 TL) was 8.49, 8.33, 8.08 and 8.10 kb, respectively. TL became significantly decreased after 4 (p = 0.005) and 6 (p = 0.026) cycles of chemotherapy. The mean value of DeltaTL before and after completion of chemotherapy (t0 TL - t3 TL) was 0.46 kb. DeltaTL has a significant correlation with good treatment response (r = 0.448, p = 0.005) and the frequency of severe neutropenia (r = 0.417, p < 0.05). Consequently, TL of peripheral blood mononuclear cells was decreased by the repetitive nonmyeloablative standard-dose chemotherapy in solid-cancer patients without bone marrow metastasis, and DeltaTL was associated with good treatment response and neutropenia severity.
Yoon
So Young
SY
Department of Internal Medicine, Konkuk University Hospital, Seoul, Korea.
Sung
Hwa Jung
HJ
Park
Kyong Hwa
KH
Choi
In Keun
IK
Kim
Seok Jin
SJ
Oh
Sang Cheul
SC
Seo
Jae Hong
JH
Choi
Chul Won
CW
Kim
Byung Soo
BS
Shin
Sang Won
SW
Kim
Yeul Hong
YH
Kim
Jun Suk
JS
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000097:blood; D015331:Cohort Studies; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology* / Q000401:mortality; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology*; D011336:Probability; D011446:Prospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D019098:Telomerase / Q000378:metabolism*; D016615:Telomere / Q000187:drug effects*; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D019098:Telomerase